Stock Alert: Vir Biotechnology Closes Enrollment In COVID-19 Vaccine Trial

By RTTNews Staff Writer   ✉   | Published:

Shares of Vir Biotechnology Inc. (VIR) are losing nearly 30% on Wednesday morning after the company said it has stopped enrollment in COVID-19 vaccine trial.

VIR is currently trading at $41.21, down $16.53 or 28.63%, on the Nasdaq.

Vir Biotechnology and GlaxoSmithKline plc (GSK) provided an update on phase 3 trial of its potential COVID-19 vaccine VIR-7831.

The companies said that while VIR-7831 met initial pre-specified criteria to continue to the next phase of the trial and there were no reported safety signals, sensitivity analyses of the available data raised concerns about the magnitude of potential benefit.

The independent Data and Safety Monitoring Board has recommended that the VIR-7831 arm of the trial be closed to enrollment while the data mature.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Next Story
Editors Pick
FDA Accelerates Efforts To Issue EUA For More COVID-19 Home Tests
The U.S. Food and Drug Administration is hastening its efforts to make available more at-home testing options in response to the ongoing COVID-19 pandemic. All At-Home Covid-19 Tests being used now are authorized only for emergency use, and not cleared or fully approved by the FDA. The recent granting of EUA for the Quidel Corp.'s QuickVue At-Home COVID-19 Test is one example.
Dollar Tree, Wendy's Q4 Revenues Miss Estimates
Dollar Tree Inc. (DLTR) Wednesday reported a profit for the fourth-quarter that climbed 309 percent from last year, while Wendy's Co. (WEN) posted a profit that grew about 46.0 percent from the prior year. Dollar Tree has increased its share repurchase authorization by $2.0 billion. Wendy's expects profit for fiscal year 2021 to be below analysts' expectations.
Boston Scientific To Buy Global Surgical Business Of Lumenis For $1.07 Bln Cash - Quick Facts
Medical devices company Boston Scientific Corp. (BSX) agreed Wednesday to acquire the global surgical business of Israel-based Lumenis LTD from an affiliate of Baring Private Equity Asia (BPEA) for an upfront cash payment of $1.07 billion, subject to closing adjustments. Lumenis is a privately-held...